Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|August 26, 2017
Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) scoreEriko Sato, Noriyoshi Iriyama, Michihide Tokuhira, et al.
Leukemia Research|January 23, 2017
Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study GroupNoriyoshi Iriyama, Michihide Tokuhira, Tomoiku Takaku, et al.
Plant & Cell Physiology|August 21, 2025
The rice BRITTLE CULM 4 gene encodes a membrane protein involved in cellulose synthesis in the secondary cell wallMasatoshi Yamaguchi, Ami Sato, Daisuke Takahashi, et al.
Medical Oncology (Northwood, London, England)|February 15, 2018
Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phaseMichihide Tokuhira, Yuta Kimura, Keiji Sugimoto, et al.
Hematology (Amsterdam, Netherlands)|July 16, 2005
NK-cell neoplasms in JapanKazuo Oshimi, Keisei Kawa, Shigeo Nakamura, et al.
Medical Oncology (Northwood, London, England)|September 9, 2018
Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysisNoriyoshi Iriyama, Kei-Ji Sugimoto, Eriko Sato, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|December 3, 2010
Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation ; clinical, flow cytometry, and histopathological findings of 11 casesMinoru Kojima, Eriko Sato, Kazuo Oshimi, et al.
Oncology Reports|October 4, 2019
Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysisMaho Ishikawa, Noriyoshi Iriyama, Michihide Tokuhira, et al.
Cancer Medicine|October 10, 2020
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohortEriko Sato, Noriyoshi Iriyama, Michihide Tokuhira, et al.
Annals of Hematology|June 28, 2018
Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group databaseIsao Fujioka, Tomoiku Takaku, Noriyoshi Iriyama, et al.
Pageof 10